Ongoing Studies

Our ongoing research studies aim to develop and evaluate a novel, multimodal neuroimaging framework (specifically, using Magnetic Resonance Imaging or MRI, which does not contain any ionizing radiation) for testing GABAergic and glutamatergic* medications for conditions marked by GABAergic/glutamatergic dysfunction (e.g., Bipolar Disorder, heavy alcohol or cannabis use). These investigations will utilize safe, FDA-approved medications that have been demonstrated to normalize cortical GABA and/or glutamate concentrations in individuals with epilepsy and cocaine dependence, respectively, in a difficult-to-treat population characterized by unique GABAergic and glutamatergic disturbances: individuals with Bipolar Disorder who also drink alcohol and/or use marijuana or other drugs.**

Image of Girl Displaying Happy and Sad Emotions

Imaging Framework for Testing GABAergic/glutamatergic Drugs in Bipolar Alcoholics

This study examines the effects of the medication gabapentin and the supplement n-acetylcysteine among individuals with Bipolar Disorder who regularly drink alcohol. Participants in this study will take gabapentin, n-acetylcysteine, and matched placebo (one at a time) for 5 days each. There are 8 study visits, including 3 MRI scans.

Image of beer glasses

Contact Us

If you are interested in participating in Bipolar Disorder research, please call 843-792-7500 or email bipolardisorder@musc.edu.